Abstract

EE379 Economic Evaluation of Nubeqal for the Treatment of Adult Patients With Non-Metastatic Castration Resistant Prostate Cancer in the Mexican Context

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Jaleh Fallah ...
The Lancet. Oncology | VOL. 22
Jaleh Fallah, et. al.Jaleh Fallah ...
01 Sep 2021
The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective
Brendan A Yanada ... Niall M Corcoran
Seminars in urologic oncology | VOL. 42
Brendan A Yanada, et. al.Brendan A Yanada ... Niall M Corcoran
29 Mar 2024
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
Arif Hussain ... Christopher Logothetis
Prostate cancer and prostatic diseases | VOL. 24
Arif Hussain, et. al.Arif Hussain ... Christopher Logothetis
07 Oct 2020
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva ... David Agus
Investigational new drugs | VOL. 30
Ajjai Alva, et. al.Ajjai Alva ... David Agus
04 Nov 2010
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers